Simrat Randhawa Sells 23,124 Shares of Dianthus Therapeutics (NASDAQ:DNTH) Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) EVP Simrat Randhawa sold 23,124 shares of the stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $106.41, for a total value of $2,460,624.84. Following the completion of the sale, the executive vice president directly owned 4,000 shares of the company’s stock, valued at approximately $425,640. This represents a 85.25% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Dianthus Therapeutics Stock Performance

NASDAQ DNTH opened at $108.10 on Friday. The stock’s fifty day moving average is $105.23 and its two-hundred day moving average is $89.08. The firm has a market capitalization of $5.91 billion, a P/E ratio of -26.05 and a beta of 1.24. Dianthus Therapeutics, Inc. has a fifty-two week low of $24.49 and a fifty-two week high of $117.88.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%.The company had revenue of $0.76 million during the quarter, compared to analyst estimates of $0.30 million. As a group, sell-side analysts forecast that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current year.

Analysts Set New Price Targets

Several research firms have weighed in on DNTH. Truist Financial boosted their target price on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Wedbush raised their price target on shares of Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an “outperform” rating in a report on Wednesday, August 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Friday, July 17th. HC Wainwright raised their target price on Dianthus Therapeutics from $130.00 to $158.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Finally, Raymond James Financial restated a “strong-buy” rating and issued a $131.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Dianthus Therapeutics has an average rating of “Moderate Buy” and an average price target of $126.92.

Institutional Trading of Dianthus Therapeutics

Several institutional investors have recently added to or reduced their stakes in DNTH. BlackRock Inc. purchased a new stake in Dianthus Therapeutics in the second quarter valued at approximately $401,990,000. California State Teachers Retirement System boosted its position in shares of Dianthus Therapeutics by 10,003.2% during the second quarter. California State Teachers Retirement System now owns 4,100,301 shares of the company’s stock worth $399,697,000 after buying an additional 4,059,717 shares during the period. Wellington Management Group LLP grew its stake in shares of Dianthus Therapeutics by 24.4% in the second quarter. Wellington Management Group LLP now owns 3,229,882 shares of the company’s stock valued at $314,849,000 after buying an additional 634,099 shares in the last quarter. Vestal Point Capital LP grew its stake in shares of Dianthus Therapeutics by 88.2% in the second quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock valued at $59,616,000 after buying an additional 1,499,931 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of Dianthus Therapeutics by 24.7% in the 4th quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock valued at $84,417,000 after buying an additional 406,254 shares during the period. Institutional investors and hedge funds own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.